Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(6850)
•••
tamaracktop
X
View Profile
View Bullboard History
Comment by
tamaracktop
on Jan 11, 2023 7:53pm
RE:Dr. Peter Dicpinigaitis Appointed to the Advisory Board
He looks very much like a young Gene Hackman.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 11, 2023 6:22pm
RE:Dr. Peter Dicpinigaitis Appointed to the Advisory Board
Yes, the good doctor has world class credentials. However, the bottomline goes something like this: When does/will the trial actually start? In how many different countries will they
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Jan 11, 2023 3:09pm
RE:Dr. Peter Dicpinigaitis Appointed to the Advisory Board
Definitely. It's notable that while he has extensive experience in all aspects of clinical medicine, a major focus of his clinical research for over 25 years has been in the area of cough
...more
(36)
•••
Justdosomedd
X
View Profile
View Bullboard History
Post by
Justdosomedd
on Jan 11, 2023 1:26pm
Dr. Peter Dicpinigaitis Appointed to the Advisory Board
It’s important for a company to have a strong advisory board to help guide them toward the right path. $AGN.C just appointed Dr. Peter Dicpinigaitis to the board, and he certainly has the
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 11, 2023 7:00am
New Press Release - Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
VANCOUVER, British Columbia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has appointed Dr. Peter...
read article.
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Jan 10, 2023 5:45pm
$AGN.c releases phase 2b details of the chronic cough study
$AGN.c releases phase 2b details of the chronic cough study of Ifenprodil. https://www.youtube.com/watch?v=REtP6b3LwY0&ab_channel=Proactive $AGN.c has announced it is
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 10, 2023 4:55pm
RE:RE:RE:RE:Real World Math Doesn't Apply To Algernon Pharmaceuticals
My apology for the name calling. Follow-up for "arguments" sake. Let's say you are right about rhe likely explained to you by management interpretation of the SEC filing news release
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 10, 2023 4:29pm
RE:RE:RE:RE:Real World Math Doesn't Apply To Algernon Pharmaceuticals
Dude, does 2+2=4 in your world? The math doesn't lie. You can't get to a 10M dollar raise of a subsidiary valued at 20M without offering 50% of all shares. What you claim to be an argument is
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Jan 10, 2023 4:05pm
AGN CEO discussing Phase 2b of ifenprodil for chronic cough
Check out AGN's CEO Christopher Moreau on Proactive
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Comment by
waves1
on Jan 10, 2023 4:01pm
RE:Potential for ODD w/ Phase2b chronic cough study?
AGN trading green today following this news!
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 10, 2023 2:14pm
RE:RE:RE:Real World Math Doesn't Apply To Algernon Pharmaceuticals
Argument should never debate with invective. Over and out!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 10, 2023 2:00pm
New Press Release - Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil
(NewsDirect)Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre...
read article.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on Jan 10, 2023 12:42pm
RE:RE:Real World Math Doesn't Apply To Algernon Pharmaceuticals
Some people will always be morons no matter how much they're shown the way.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on Jan 10, 2023 11:16am
RE:Real World Math Doesn't Apply To Algernon Pharmaceuticals
The $20 valuation is based on comparables at Stage 1 research while the cash call occurs at Stage 2. if Stage 2 results mirror Stage 1, there will be a massive increase in imputed
...more
(38)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Jan 09, 2023 3:33pm
AGN featured in The Power Play by The Market Herald
The Power Play by The Market Herald just released this interview with Algernon Pharmaceuticals (AGN.c AGNPF) where they discuss their plans for a Phase 2b clinical study of their Ifenprodi drug for
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed
EnviroGold Global Announces Appointment of Chief Operating Officer